Hospital Universitario Antonio Pedro
Niterói, Rio de Janeiro, 24033-900, Brazil
NCT Number: NCT03939078
Menopause is a woman's hormonal status one year after her ovulatory failure, when the decrease of circulating estrogen levels leads to a group of symptoms named Genitourinary Syndrome of Menopause (GSM), such as: vaginal dryness, dyspareunia, dysuria, epithelial fragility with recurrent bleedings, loss of genital elasticity and pH alterations causing recurrent infections. The CO2 laser is a fractional ablative source of light, capable of inducing neocollagenesis within the skin, reversing atrophies, increasing blood supply and reorganizing the architectural structure of the treated epithelium. Recent studies in the laser field show great improvement of the SGM, with satisfying results in female's sexual disfunction. Nevertheless, there is still a lack of studies that show, at the same time, the improvement in both patient's subjective reports and objective measurements, such as cytology, histology and immunohistochemistry. This study aims to thoroughly analyze the benefits of the CO2 laser in the treatment of the GMS, comparing the improvement found in questionnaires to the results of cytology, histology and immunohistochemistry for collagen I and III from vaginal biopsies before and after the laser treatment. Therefore, fourteen women after menopause complaining of symptoms of the GSM were selected from the ambulatory of the Hospital Universitário Antônio Pedro. The patients will be submitted to three CO2 intravaginal laser (Femilift®), with a 30-days interval between them. Biopsies of the vaginal wall will be taken one month before the start and one month after the end of the laser sessions, and material will be sent to histology, cytology and immunohistochemistry analysis. Results obtained will be compared to the patients' reports, in order to evaluate subjective and objective improvement due to the treatment.
Looking for future studies?
Notify Me40 year–70 year
Female
Observational
Niterói, Rio de Janeiro, 24033-900, Brazil
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3 intravaginal fractional ablative CO2 laser sessions, with one month interval between them.
Time frame: 1 month after the last (3rd) laser section
Reversion of vaginal atrophy by the laser stimulation, with increasing layers of epithelial cells, increased collagen deposition and improvement in vascularization.
Time frame: 1 month after the third and last laser section
Improvement in urine involuntary loss, the so called stress incontinence
Universidade Federal Fluminense
Other
Fractional Ablative CO2 Laser in the Treatment of the Genitourinary Syndrome of Menopause
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05058313
Atrophic Vaginitis, Female Urogenital Diseases
Nîmes, France
View Trial DetailsNCT05916820
Behavior, Behavioral Symptoms
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT01918072
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
West Los Angeles, California, United States
View Trial DetailsNCT01050465
Acne Vulgaris, Acneiform Eruptions
View Trial Details